Search Result

Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

anti-GD2 antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD2 (2) CD3 (1)
By Research Areas:	Cancer (5)

2

Inhibitors & Agonists

4

Inhibitory Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

M3554	CD2	Cancer
M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody and has anti-tumor activity. The cytotoxicity of M3554 against the GD2-positive neuroblastoma cell line CHP134 was in the subnanomolar IC₅₀ range.

Cat. No.	Product Name	Target	Research Area

Dinutuximab Unituxin; APN-311	Inhibitory Antibodies	Cancer
Dinutuximab (Unituxin; APN-311) is a chimeric, human-murine, anti-GD2 monoclonal antibody. Dinutuximab potently enlongs event-free survival and overall survival, in high-risk neuroblastoma treatment, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) .

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

Lorukafusp alfa APN-301; hu14.18-IL2; EMD 273063	Inhibitory Antibodies	Cancer
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .

hu14.18 (K322A)	Inhibitory Antibodies	Cancer
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2025 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us